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Mycobacterium avium subsp. paratuberculosis (MAP) is the etiological agent of Johne’s disease in ruminants. Recent studies have
linked MAP to type 1 diabetes (T1D) in the Sardinian population. The aim of this study was to investigate the prevalence of MAP
infection in a T1D cohort from continental Italy compared with healthy control subjects. 247 T1D subjects and 110 healthy controls
were tested for the presence of MAP. MAP DNA was detected using IS900-specific polymerase chain reaction (PCR). The presence
of antibodies towards a MAP antigen, heparin binding hemoagglutinin (HBHA), was detected by ELISA. We demonstrated a
higher MAP DNA prevalence in plasma samples from T1D patients and a stronger immune response towards MAP HBHA, com-
pared with healthy control subjects. Moreover, in the recent onset patients, we observed an association between anti-MAP anti-
bodies and HLA DQ2 (DQA1 0201/DQB1 0202). These findings taken together support the hypothesis of MAP as an environ-
mental risk factor for the development of T1D in genetically predisposed subjects, probably involving a mechanism of molecular
mimicry between MAP antigens and pancreatic islet β-cells.
1. Introduction
Type 1 diabetes (T1D) is an autoimmune endocrine disorder
characterized by T cell infiltration of the pancreas and pro-
duction of autoantibodies [1]. Several loci, primarily HLA,
and environmental factors might be responsible for the
disease manifestation [2, 3]. Indeed, the clinical onset of T1D
is described as a sequence of multiple environmental insults
in genetically susceptible subjects [3].
It is common knowledge that epitope mimicry is the
mechanism by which an infectious agent exposing epitopes
immunologically very similar to the antigenic determinants
of the host induces a loss of tolerance to self antigens,
triggering an autoimmune response [4, 5]. The epidemio-
logical data suggest that some viruses such as enteroviruses,
and more specifically coxackieviruses, but also rotaviruses,
cytomegalovirus, parvovirus, and encephalomyocarditis
virus might have a role in the T1D pathogenesis [3]. To a
lesser extent, also bacteria have been indicated as environ-
mental trigger of T1D onset. Direct evidence exists in rod-
ents, that indeed diabetes is aggravated under specific patho-
gen-free conditions or upon administration of antibiotics
[6]. In other studies, however, administration of antibiotics
prevented diabetes [7, 8].
Recently, Mycobacterium avium subsp. paratuberculosis
(MAP) has been proposed as a new environmental trigger
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Table 1: Distribution of IS900 PCR (MAP genome) detection in a cohort of Type 1 Diabetes (T1D) patients compared to healthy controls




T1D 87,9% (n = 217) 12,1% (n = 30) 100% (n = 247)
P < 0, 033
CTR 95,5% (n = 105) 4,5% (n = 5) 100% (n = 110)
that might contribute to T1D pathogenesis [9, 10]. MAP
causes a chronic granulomatosis enteritis, known as Johne’s
disease, in ruminants [11]. This pathogen is characterized by
the ability to survive pasteurization and chlorination [12], so
that it can be detected in milk and dairy products obtained
from infected ruminants, that are asymptomatic reservoir
[11, 12]. It is well known that in Sardinia MAP infection is
endemic in sheep husbandry and that this pathogen is asso-
ciated with Crohn’s disease [13–15], suggesting that MAP
could be an environmental factor [16, 17]. MAP infection
is highly prevalent in T1D patients in Sardinia, one of the
regions with the highest T1D incidence worldwide. Indeed,
MAPDNAwas isolated from blood in 63% of Sardinian T1D
patients, but only in 16% of healthy controls [9]; the MAP
envelope protein MptD can be detected in the blood of 47%
Sardinian T1D patients, but in a smaller proportion of type
2 diabetes (T2D) patients (8%) and healthy controls (13%)
[16, 18]; and MAP bacilli can be cultured from blood [16].
In addition, recent studies on Sardinian population have
demonstrated an association between MAP and multiple
sclerosis [19, 20], extending its role as environmental trigger
of diﬀerent autoimmune diseases.
We could confirm the association betweenMAP and T1D
in a cohort of children from continental Italy, evaluating the
presence of MAP DNA and of anti-MAP antibodies in the
sera of patients and healthy subjects.
2. Materials and Methods
2.1. Patient and Control Sera Samples. A total of 357 parti-
cipants comprising of 247 with T1D and 110 healthy con-
trols, attending the Pediatric Diabetes Unit of Tor Vergata
University Hospital of Rome, were tested for the presence
of MAP. Blood from patients was centrifuged, and serum
supernatants were used for enzyme-linked immunosorbent
assay (ELISA); the remaining sera were aliquoted and stored
frozen at −20◦C for short-term storage (<6 months) and
−80◦C for long-term storage (>6 months). A second blood
sample was used to collect PBMCs for DNA extraction. Writ-
ten informed consent to participate to the study was obtained
from all subjects or from their parents, according to the
Institutional Ethical Committee.
2.2. Protein Expression and Purification. MAP heparin bind-
ing haemagglutinin was purified as described earlier [21] The
HBHA was subcloned in pET15 (Novagen Inc., Madison,
WI), and the recombinant histidine-tagged protein was puri-
fied by nickel chromatography according to the standard pro-
tocols [21].
2.3. MAP IS900 Amplification. The presence of MAP-specific
IS900 signature using total DNA extracted from PBMCs
was performed as previously published [9, 14]. Diﬀerent
amplicons obtained by the second-round nested PCR were
sequenced to confirm IS900 identity.
2.4. ELISA. An indirect ELISA to detect antibodies anti-
MAP HBHA was performed as described previously [21].
ELISA was performed in 96-well microplates (Nunc-
Immuno plate). Purified HBHA protein was diluted in
carbonate bicarbonate buﬀer (Sigma-Aldrich) at a final con-
centration of 5 μg/mL and used as an antigen. Each well
was coated with 50 μL of diluted antigen overnight at 4◦C.
The next day, the unabsorbed antigen was discarded, and
wells were blocked with 5% nonfat-dried milk (Sigma-
Aldrich) at 37◦C for 1 h. Plates were washed three times
with 200 μL phosphate-buﬀered saline-Tween (PBS-T) (PBS-
0.05% Tween 20) before 100 μL of diluted serum (1 : 100 in
PBS-T) was added to each well. After 2 h, plates were washed
five times with PBS-T and incubated for 1 h with 100 μL of
anti-human immunoglobulin G alkaline phosphatase anti-
body (Sigma-Aldrich) diluted 1 : 1,000 in PBS-T. Five rounds
of washing were performed, and 200 μL of Sigma Fast p-
nitrophenyl phosphatase substrate was added to each well. As
the color developed, plates were read at 405 nm on a VERSA
Tunable Max microplate reader (Molecular Devices). Cut-
oﬀ was set at 0.67 and calculated as described previously
[15, 18, 21].
2.5. Statistical Analysis. The associations of the frequencies
were evaluated by Fisher’s exact (2 × 2 tables) and chi-
square tests. A P-value ≤ 0.05 was considered statistically
significant. Analyses were performed using SPSS 13.0 (SPSS,
Inc., Chicago, IL).
3. Results
We evaluated the presence of MAP DNA in the PBMCs of
247 T1D patients and 110 healthy subjects. We found that
MAP DNA (IS900 PCR) was detected in the sera of 30
T1D patients (12.1%) and 5 healthy controls (4.5%). Our
results (Table 1) indicated that the presence of MAP DNA is
significantly associated with T1D (P = 0, 033). Anti-HBHA
antibodies (HBHA is a membrane MAP antigen involved in
virulence) were also searched by ELISA. We tested the sera of
247 T1D patients and 110 healthy controls and the results,
expressed as optical density (OD), are reported in Table 2.
The HBHA antigen gave strong ELISA values (cut-oﬀ titer
value of 0.67) in 76 patients (30.8%) but only in 5 healthy
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Table 2: HBHA antigen (expressed as OD values) positivity in a cohort of Type 1 Diabetes patients (T1D) compared to healthy controls




T1D 69,2% (n = 171) 30,8% (n = 76) 100% (n = 247)
P < 0, 0000
CTR 95,5% (n = 105) 4,5% (n = 5) 100% (n = 110)
Table 3: Combination of distribution (by chi-square test) of IS900 PCR (MAP genome) and HBHA MAP antigen in a cohort of Type 1
diabetes patients (T1D) compared to healthy controls (CTR). Percentage and absolute values.
Combination (PCR versus HBHA antigen)
Total P value
0-0 1-0 0-1 1-1
T1D 60,7% (n = 150) 27,1% (n = 67) 8,5% (n = 21) 3,6% (n = 9) 100% (n = 247)
P < 0, 0000
CTR 90,9 (n = 100) 4,5% (n = 5) 4,5% (n = 5) 0% (n = 0) 100% (n = 110)
0: negative, 1: positive.
Table 4: Association between the positivity of anti-MAP antibodies and the presence of HLA DQA1∗0201/DQB1∗0202 in a group of






0 92,6% (n = 25) 7,4% (n = 2) 100% (n = 27)
P < 0, 0000
1 61,5% (n = 8) 38,5% (n = 5) 100% (n = 13)
Not onset
0 84,7% (n = 105) 15,3% (n = 19) 100% (n = 124)
P = ns
1 77,6% (n = 45) 22,4% (n = 13) 100% (n = 58)
HBHA OD: 0< 0,67, 1≥ 0,67.
subjects (4.5%). These findings confirm the strong asso-
ciation between the presence of anti-MAP antibodies and
T1D (P < 0.0000). Interestingly, only in T1D patients sera,
a positivity of both MAP DNA and antibodies anti-MAP
was observed (P = 0, 0000, Table 3). Considering the high
frequencies of MAP antibodies positive subjects, we analyzed
by chi-square test the association between these values
and the diﬀerent parameters that characterized our cohort
and we did not find significant association with any of the
variables investigated (data not shown). When we stratified
our cohort in 40 patients with newly diagnosed T1D (within
six months after the onset) and in 182 patients 6months after
the onset, we did not observe any diﬀerence in MAP DNA
and antibodies anti-MAP positivity between the two groups
(data not shown). Interestingly, in the newly diagnosed T1D
patients group, we found a significant correlation between
the antibodies anti-MAP positivity and the presence of HLA
DQA1∗0201/DQB1∗0202 (Table 4).
4. Discussion
MAP is the etiological agent of paratuberculosis, a chronic
granulomatosis enteritis in ruminants [11]. The bacteria is
widely disseminated and it can be detected in milk and dairy
products [12].
Originally, MAP has been associated with immune relat-
ed disorders, such as Crohn’s disease [13, 14, 17, 22]. Recent-
ly, diﬀerent works suggested that MAP may be considered
a bacterial risk factor involved in the development of T1D,
but this relationship was demonstrated only within the Sar-
dinian population [9, 10, 18, 21, 23, 24].
Here, we showed that an association between MAP and
T1Dwas observed also in a cohort of patients from continen-
tal Italy, with a genetic background diﬀerent from Sardinians.
In detail, we showed a statistical significant association bet-
ween the presence of MAP DNA and T1D and also a strong
association with the presence of anti-MAP antibodies. These
findings support the hypothesis that MAP might have a
potential role as environmental trigger of T1D. To further
test this view, we compared the prevalence of the positivity
for MAP DNA and anti-MAP antibody in patients at onset
and with a long-term disease, and we did not find signifi-
cant diﬀerences. However, due to the numerical imbalance
between the two groups, we believe that this data does not
reflect the real distribution of MAP frequencies in the whole
patient population. It would be interesting to perform a
targeted study that might specifically address the question
whether MAP infection is temporally related to the onset
of the disease. The fact that only in T1D patients sera a
positivity of both MAP DNA and antibodies anti-MAP was
observed could link even more T1D and MAP since HBHA
homologue are present also in other mycobacteria [21] and
ELISA positivity (but negative PCR) in healthy control could
reflect a cross-reaction with environmental mycobacteria. It
is also true that PCR and ELISA have diﬀerent sensitivity and
search for diﬀerent things: IS900 MAP-specific PCR posi-
tivity reflects the presence of MAP specific DNA, ELISA
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positivity reflects a humoral response toward MAP but the
host could be actually MAP free.
Interestingly, we showed an association between anti-
MAP antibodies and HLA DQ2 (0201/0202) in patients at
onset. We might speculate that this HLA could be involved in
the MAP recognition, favouring its role as an environmental
trigger. Indeed, it is known that some HLA typing may pro-
mote molecular mimicry between microbial proteins and
islet autoantigens [2]. In line with this hypothesis, another
MAP protein, namely, MAP3865c, displays a sequence hom-
ology with the β-cell antigen zinc transporter 8 (ZnT8) [25],
which is targeted by aAbs in T1D patients [26].
In conclusion, we report for the first time the association
between T1D and MAP in a population outside Sardinia,
suggesting that there is suﬃcient indirect evidence to warrant
a focus on MAP as potential trigger in T1D.
Key Points
We demonstrated for the first time that Mycobacterium
avium subsp. paratuberculosis (MAP) is present at the onset
of T1D in a cohort of italian patients outside Sardinia. This
raises some concerns regarding the diﬀusion of MAP and its
possible involvement in triggering T1D.
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